publicações selecionadas
-
documento
- Novel genetic modifiers of SCA3/MJD: an EMS screening in a C. elegans model of the disease 2024
- Repurposing dopaminergic drugs to prevent Ataxin 3 aggregation 2023
- FastProtAct - FAST-throughput phenotypic assay to identify compounds with PROTeostasis ACTivity. 2023
- Serotonergic signaling modulation as a therapeutic approach for spinocerebellar ataxia type 3: unveiling the molecular pathways 2023
- Limited Therapeutic Impact of Intermittent Fasting and Ketogenic diets in a Mouse Model of Spinocerebellar Ataxia Type 3 2023
- Unraveling the ATXN3 interactome: clues on its contribution for physiology and disease 2023
- Identification of novel molecules with proteostasis enhancement activity using a whole-animal based fast-throughput phenotypic assay 2023
- Identification of novel molecules with proteostasis enhancement activity using a whole-animal based fast-throughput phenotypic assay. 2023
- Motor coordination and balance ameliorated after treatment of the CMVMJD135 mouse model of Spinocerebellar Ataxia Type 3 with befiradol 2022
- Novel genetic modifiers of SCA3/MJD: an EMS screening in a C. elegans model of the disease 2022
- Nuclear ATXN3 DUB Physiological Substrates: Towards Understanding Their Role In The Context Of Machado-Joseph Disease 2022
- Pre and post-symptomatic treatment with NLX-112 improved the balance and motor coordination of the CMVMJD135 mouse model of Machado-Joseph Disease 2022
- The involvement of astrocyte calcium-dependent signaling in behavior 2022
- Development of a high-throughput phenotypic assay to screen for chemical enhancers of proteostasis activity in Caenorhabditis elegans 2022
- NLX-112 improved the motor coordination and balance in a Mouse Experimental Model of Machado-Joseph Disease 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Diseases 2021
- Serotonergic signaling activation suppresses proteotoxicity 2019
- NLX-112, a novel 5-HT1A receptor agonist, suppresses pathogenesis of mutant ATXN3 in C. elegans 2019
- Finding molecular determinants supporting serotonergic modulation as a therapeutic approach in Machado Joseph Disease 2019
- A neuroprotective role played by secretome from mesenchymal stem cells against the action of a-synuclein on a Caenorhabditis elegans model of Parkinson’s Disease 2019
- Early modulation of serotonergic signaling suppresses aggregation in Spinocerebellar Ataxia 3 2019
- NLX-112, a novel 5-HT1A receptor agonist, supresses neuronal dysfunction in a C. elegans model of Spinocerebellar Ataxia 2019
- Preclinical evidence supporting serotonergic modulation as a therapeutic approach for Spinocerebellar Ataxia 3 2019
- Targeting of the Serotonin (1A) Receptor Suppresses Mutant Ataxin-3 Pathogenesis in C. elegans 2019
- Finding molecular determinants supporting serotonergic modulation as a therapeutic approach in Machado-Joseph disease 2018
- Preclinical evidence supporting early initiation of citalopram treatment in Machado-Joseph disease 2018
- The secretome of mesenchymal stem cells exerts a protective effect towards a Caenorhabditis Elegans model of Parkinson’s Disease 2018
- Serotonergic modulation of the proteostasis network and glutamatergic neurotransmission: impact on MJD 2017